Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function

Cardiology

Volumn 111, Issue 4, 2008, Pages 247-253

  Pinkau, Tobias ^a   Ndrepepa, Gjin ^a,b   Kastrati, Adnan ^a   Mann, Johannes F E ^a   Schulz, Stefanie ^a   Mehilli, Julinda ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Abciximab; Bleeding; Clopidogrel; Mortality; Percutaneous coronary intervention; Renal insufficiency

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; FIBRINOGEN RECEPTOR; HEMOGLOBIN; HEPARIN; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ASPIRIN; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; QUESTIONNAIRES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TICLOPIDINE;

EID: 55249084668     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127446     Document Type: Article

References (25)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
2. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, CLASSICS Investigators: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
3. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
4. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators. Clopidogrel for the Reduction of Events During Observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420.
5. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-2775.
6. Pinkau T, Mann JF, Ndrepepa G, Mehilli J, Hadamitzky M, Braun S, Kastrati A, Schömig A: Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. Am J Kidney Dis 2004;44:627-635.
7. Noris M, Remuzzi G: Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999;94:2569-2574.
8. Gordge MP, Faint RW, Rylance PB, Neild GH: Platelet function and the bleeding time in progressive renal failure. Thromb Haemost 1988;60:83-87.
9. Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M: Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 1996;83:351-361.
10. Mezzano D, Tagle R, Pais E, Panes O, Pérez M, Downey P, Muñoz B, Aranda E, Barja P, Thambo S, González F, Mezzano S, Pereira J: Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res 1997;88:465-472.
11. Soslau G, Brodsky I, Putatunda B, Parker J, Schwartz AB: Selective reduction of serotonin storage and ATP release in chronic renal failure patients platelets. Am J Hematol 1990:35:171-178.
12. Sreedhara R, Itagaki I, Hakim RM: Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996;27:355-364.
13. Liani M, Salvati F, Golato M, Tresca E: Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia. Nephron 1996;72:716.
14. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A, Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-238.
15. Campeau L: Grading of angina pectoris. Circulation 1976;54:522-523.
16. Cockcroft DW, Gault MH: Prediction of glomerular filtration rate from serum creatinine. Nephron 1976;16:31-41.
17. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
18. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
19. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM: Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193-1202.
20. Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, Lincoff AM, Topol EJ, Ellis SG: Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002;89:1209-1211.
21. Best PJ, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, Herzog CA, Holmes DR Jr, Berger PB: Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003;146:345-350.
22. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003;41:718-724.
23. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ, REPLACE-2 Investigators: Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005;95:581-585.
24. Frilling B, Zahn R, Fraiture B, Mark B, Dönges K, Becker T, Siegler KE, Seidl K, Rustige J, Senges J: Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 2002;89:450-452.
25. Macie C, Forbes L, Foster GA, Douketis JD: Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004;125:1616-1621.